Deciphering the pathogenesis of the COL4-related hematuric nephritis: A genotype/phenotype study.
COL4A3
COL4A5
Alport syndrome
COL4A4 gene mutations
genotype/phenotype
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
revised:
18
11
2020
received:
14
04
2020
accepted:
24
11
2020
pubmed:
29
12
2020
medline:
5
8
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Alport syndrome (ATS) is a hereditary progressive hematuric nephropathy associated with sensorineural deafness and ocular abnormalities, which is caused by mutations in the COL4A5 gene (X-linked ATS) and in two autosomal genes, COL4A4 and COL4A3, responsible of both recessive ATS and, when present in heterozygosity, of a spectrum of phenotypes ranging from isolated hematuria to frank renal disease. Retrospective analysis of the clinical and genetic features of 76 patients from 34 unrelated ATS families (11 with mutations in COL4A5, 11 in COL4A3, and 12 in COL4A4) and genotype/phenotype correlation for the COL4A3/COL4A4 heterozygotes (34 patients from 14 families). Eight (24%) of the 34 heterozygous COL4A3 and COL4A4 carriers developed renal failure at a mean age of 57 years, with a significantly lower risk than hemizygous COL4A5 or double heterozygous COL4A3/COL4A4 carriers (p < 0.01), but not different from that of the heterozygous COL4A5 females (p = 0.6). Heterozygous carriers of frameshift/splicing variants in COL4A3/COL4A4 presented a higher risk of developing renal failure than those with missense variants in the glycine domains (p = 0.015). The renal functional prognosis of patients with COL4A3/COL4A4-positive ATS recapitulates that of the X-linked ATS forms, with differences between heterozygous vs. double heterozygous patients and between carriers of loss-of-function vs. missense variants.
Sections du résumé
BACKGROUND
Alport syndrome (ATS) is a hereditary progressive hematuric nephropathy associated with sensorineural deafness and ocular abnormalities, which is caused by mutations in the COL4A5 gene (X-linked ATS) and in two autosomal genes, COL4A4 and COL4A3, responsible of both recessive ATS and, when present in heterozygosity, of a spectrum of phenotypes ranging from isolated hematuria to frank renal disease.
METHODS
Retrospective analysis of the clinical and genetic features of 76 patients from 34 unrelated ATS families (11 with mutations in COL4A5, 11 in COL4A3, and 12 in COL4A4) and genotype/phenotype correlation for the COL4A3/COL4A4 heterozygotes (34 patients from 14 families).
RESULTS
Eight (24%) of the 34 heterozygous COL4A3 and COL4A4 carriers developed renal failure at a mean age of 57 years, with a significantly lower risk than hemizygous COL4A5 or double heterozygous COL4A3/COL4A4 carriers (p < 0.01), but not different from that of the heterozygous COL4A5 females (p = 0.6). Heterozygous carriers of frameshift/splicing variants in COL4A3/COL4A4 presented a higher risk of developing renal failure than those with missense variants in the glycine domains (p = 0.015).
CONCLUSION
The renal functional prognosis of patients with COL4A3/COL4A4-positive ATS recapitulates that of the X-linked ATS forms, with differences between heterozygous vs. double heterozygous patients and between carriers of loss-of-function vs. missense variants.
Identifiants
pubmed: 33369211
doi: 10.1002/mgg3.1576
pmc: PMC8077073
doi:
Substances chimiques
Collagen Type IV
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1576Informations de copyright
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Clin Genet. 2014 Sep;86(3):252-7
pubmed: 24033287
Clin Kidney J. 2020 Feb 10;13(6):1025-1036
pubmed: 33391746
J Clin Med. 2019 Feb 03;8(2):
pubmed: 30717457
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Am Soc Nephrol. 2013 Feb;24(3):364-75
pubmed: 23349312
Kidney Int. 1996 Nov;50(5):1445-63
pubmed: 8914010
J Am Soc Nephrol. 2003 Oct;14(10):2603-10
pubmed: 14514738
Eur J Hum Genet. 2012 Jan;20(1):50-7
pubmed: 21897443
J Am Soc Nephrol. 2000 Apr;11(4):649-57
pubmed: 10752524
Kidney Int Rep. 2018 Aug 22;3(6):1239-1241
pubmed: 30450445
J Am Soc Nephrol. 2014 Dec;25(12):2740-51
pubmed: 24854265
Kidney Int. 2018 May;93(5):1045-1051
pubmed: 29551517